Results

eNauka >  Rezultati >  HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome
Naziv: HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome
Autori: Tobias, Joshua; Kundi, Michael; Garner-Spitzer, E; Zielinski, Christoph; Maglakelidze, Marina; Andric, Zoran G  ; Petrovic, Zeljko M; Nagarkar, R; Chawla, T; Chong, LMO;
Nixon, B; Yavrom, S; Ede, NJ; Wiedermann, Ursula;
Godina: 2023
Publikacija: ANNALS OF ONCOLOGY
ISSN: 0923-7534 Annals of Oncology Pretraži identifikator
Tip rezultata: Konferencijski rad
Kolacija: vol. 34 str. S4-S4
DOI: 10.1016/j.annonc.2023.04.035
WoS-ID: 001037960400481
URI: https://enauka.gov.rs/handle/123456789/808000
Izvor metapodataka: (Preuzeto iz Nasi u WoS)
M-kategorija: 
Mp kategorija će biti prikazana naknadno.

4
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Google ScholarTM

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.